[Skip to content]

Print this page

NICE Technology Appraisals

This is a list of the published NICE technology appraisals. Technology appraisals are recommendations on the use of new and existing medicines and treatments within the NHS.

NICE TAs: 1-20;  21-4041-6061-8081-100101-120121-140141-160161-180181-200201-220221-240;  241-260 261-280; 281-300; 301-320; 321-340 ; 341-360 ; 361-380

NICE TAs 301-320



DHFT Formulary link

East Midlands Cancer Network link (cancer drugs only)


 Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271) (TA301)

11.8.2 Ocular diagnostic and peri-operative preparations  



 Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)

Not recommended by NICE



 Teriflunomide for treating relapsing-remitting multiple sclerosis (TA303)

8.2.4 Other Immunomodulating Drugs 



 Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (TA304)

 Not pharmacy


 Aflibercept for treating visual impairment caused by macular oedema  secondary central retinal vein occlusion (TA305) 

11.8 Miscellaneous ophthalmic preparations


 Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma (TA306)

   DHFT protocol

Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

Not recommended by NICE

 EMCN algorithm

Rituximab in combination with glucocorticoids for treating antineutrophil cytoplasmic antibody-associated vasculitis (TA308)

8.2.3 Rituximab & Alemtuzumab


Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (TA309)

Not recommended by NICE

 EMCN algorithm

Afatinib for treating epidermal growth factor receptor mutationpositive locally advanced or metastatic non-small-cell lung cancer (TA310)


 EMCN algorithm

Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

   DHFT protocol

Alemtuzumab as an option for treating adults with active relapsing–remitting multiple sclerosis (TA312)

8.2 Drugs affecting the immune respons


Ustekinumab for treating active psoriatic arthritis (TA313)

Not recommended by NICE


Implantable cardioverter defibrillators (TA314)

No drug implications


Canagliflozin is recommended as an option for treating type 2 diabetes (TA315) Other anti-diabetics  

Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen (TA316)

   EMCN algorithm

Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)

 2.9 Antiplatelet drugs


Lubiprostone for treating chronic idiopathic constipation (TA318)

 1.6 Laxatives


Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

   EMCN algorithm

Dimethyl fumarate for active-relapsing multiple sclerosis (TA320)

8.2.4 Other Immunomodulating Drugs